Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTT-3: Interferon beta-1a plus remdesivir vs remdesivir alone in hospitalized adults with COVID-19
jRCT2031200092Completed
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Aug 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir + interferon beta-1a with Remdesivir + placebo (2 arms). Primary endpoints: Time to recovery, Clinical status at Day 15 (8-point ordinal scale) and 1 more. Started Aug 2020; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200092.